(PROG) – Globe Newswire
-
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
-
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
-
Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.
-
Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.
-
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms
-
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms
-
Progenity to Become Biora Therapeutics as it Completes Transformation
-
Progenity to Become Biora Therapeutics as it Completes Transformation
-
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
-
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
-
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
-
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
-
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
-
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
-
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
-
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
-
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22
-
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22
-
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
-
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
-
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
-
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
-
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
-
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
-
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
-
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
-
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
-
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
-
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
-
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
-
Progenity Announces New Patent for Single-Molecule Detection Technology
-
Progenity Announces New Patent for Single-Molecule Detection Technology
-
Progenity Strengthens its Liquidity Position
-
Progenity Strengthens its Liquidity Position
-
Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results
-
Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results
-
Progenity Appoints Adi Mohanty as Chief Executive Officer
-
Progenity Appoints Adi Mohanty as Chief Executive Officer
-
Progenity Announces Appointment of Jill Howe to its Board of Directors
-
Progenity Announces Appointment of Jill Howe to its Board of Directors
-
Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update
-
Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update
-
Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock
-
Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock
-
Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference
-
Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference
Back to PROG Stock Lookup
